Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 14, 2025

Brilliant Violet 510(TM) anti-human CD14

RRID:AB_2561946 Type: Antibody

Proper Citation

(BioLegend Cat# 301842, RRID:AB_2561946)

Antibody Information

URL: http://antibodyregistry.org/AB_2561946

Proper Citation: (BioLegend Cat# 301842, RRID:AB_2561946)

Target Antigen: CD14

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-human CD14

Description: This monoclonal targets CD14

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone M5E2

Antibody ID: AB_2561946

Vendor: BioLegend

Catalog Number: 301842

Alternative Catalog Numbers: 301841

Record Creation Time: 20231110T035226+0000

Record Last Update: 20240725T040705+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-human CD14.

No alerts have been found for Brilliant Violet 510(TM) anti-human CD14.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Dacon C, et al. (2025) Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein. Science (New York, N.Y.), 387(6729), eadr0510.

Lederhofer J, et al. (2024) Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. Immunity, 57(3), 574.

Müller TR, et al. (2024) Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant. Cell host & microbe, 32(2), 156.

MacDonald L, et al. (2024) Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis. Immunity, 57(12), 2843.

Wang LT, et al. (2024) Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5. Cell, 187(18), 4981.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graftversus-host disease by inhibiting pathogenic T cell responses. Cell reports, 44(1), 115102.

Adamo S, et al. (2023) Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox. Cell host & microbe, 31(6), 928.

Takata H, et al. (2023) An active HIV reservoir during ART is associated with maintenance of HIV-specific CD8+ T cell magnitude and short-lived differentiation status. Cell host & microbe, 31(9), 1494.

Touizer E, et al. (2023) Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. iScience, 26(1), 105862.

Ahmed A, et al. (2023) BCG revaccination in adults enhances pro-inflammatory markers of

trained immunity along with anti-inflammatory pathways. iScience, 26(10), 107889.

Kirosingh AS, et al. (2023) Malaria-specific Type 1 regulatory T cells are more abundant in first pregnancies and associated with placental malaria. EBioMedicine, 95, 104772.

Silk SE, et al. (2023) Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. Med (New York, N.Y.), 4(10), 668.

Tan ZC, et al. (2023) Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates. Cell reports, 42(7), 112734.

Dacon C, et al. (2023) Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. Cell host & microbe, 31(1), 97.

Matassoli F, et al. (2023) High frequency of HIV precursor-target-specific B cells in sub-Saharan populations. Cell reports, 42(12), 113450.

Ols S, et al. (2023) Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. Immunity, 56(10), 2425.

van der Ploeg K, et al. (2022) TNF-?+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell reports. Medicine, 3(6), 100640.

Lovelace SE, et al. (2022) Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses. iScience, 25(10), 105067.

Zhou C, et al. (2022) Focused B cell response to recurring gluten motif with implications for epitope spreading in celiac disease. Cell reports, 41(4), 111541.

Gao Y, et al. (2022) Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity, 55(9), 1732.